Literature DB >> 28089195

Cumulative volumetric analysis as a key criterion for the treatment of brain metastases.

Il Kyoon Kim1, Robert M Starke2, Donald A McRae3, Nadim M Nasr3, Anthony Caputy4, George D Cernica3, Robert L Hong3, Jonathan H Sherman5.   

Abstract

BACKGROUND: Recent studies have demonstrated diminished cognitive function, worse quality of life, and no overall survival benefit from the addition of adjuvant whole brain radiation therapy (WBRT) to stereotactic radiosurgery (SRS) in the management of brain metastases. This study analyzes the treatment outcome of SRS, specifically CyberKnife Radiosurgery, based on the total tumor volume compared to the absolute number of lesions.
METHODS: A retrospective analysis of hospital records at Virginia Hospital Center for patients with brain metastases who underwent CyberKnife Radiosurgery between June 2008 and June 2014 was performed. Previous treatment history, metastatic tumor dimensions, and outcomes were recorded. Predictors of neurological defects, local tumor progression, and overall survival were assessed with univariate and multivariate analysis.
RESULTS: We identified 130 adult patients with a median age of 61.5years and a median follow-up of 7.1months. Unfavorable outcomes such as death, tumor progression, or neurological defect showed correlation with cumulative tumor volume greater than the median volume of 7cc (p<0.05). Worsening neurological defects showed an association with an increased number of lesions (p<0.02) and age (p<0.05). For local tumor progression, patients who have received WBRT were less likely to progress (.74, 95% CI, .48, 1.10), while those who received chemotherapy (1.48 95% CI, .98, 2.26), or surgery (1.56 95%, CI .98, 2.47) without WBRT were more likely to progress.
CONCLUSIONS: Our data suggest that a cumulative tumor volume greater than 7cc correlates with worse outcomes following CyberKnife Radiosurgery. In addition, WBRT appears to have a role in improved survival for patients with increased tumor burden. A prospective study is warranted to validate these findings.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Brain metastasis; CyberKnife; Oncology; Stereotactic radiosurgery

Mesh:

Year:  2017        PMID: 28089195     DOI: 10.1016/j.jocn.2016.12.006

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  4 in total

1.  Factors influencing the outcome of stereotactic radiosurgery in patients with five or more brain metastases.

Authors:  E Hamel-Perreault; D Mathieu; L Masson-Cote
Journal:  Curr Oncol       Date:  2019-02-01       Impact factor: 3.677

2.  Impact of CyberKnife Radiosurgery on Overall Survival and Various Parameters of Patients with 1-3 versus ≥ 4 Brain Metastases.

Authors:  Judith Murovic; Victoria Ding; Summer S Han; John R Adler; Steven D Chang
Journal:  Cureus       Date:  2017-10-24

Review 3.  Operative and peri-operative considerations in the management of brain metastasis.

Authors:  Eric W Sankey; Vadim Tsvankin; Matthew M Grabowski; Gautam Nayar; Kristen A Batich; Aida Risman; Cosette D Champion; April K S Salama; C Rory Goodwin; Peter E Fecci
Journal:  Cancer Med       Date:  2019-09-30       Impact factor: 4.452

4.  Shifting paradigms: whole brain radiation therapy versus stereotactic radiosurgery for brain metastases.

Authors:  Ashwin Shinde; David Akhavan; Mina Sedrak; Scott Glaser; Arya Amini
Journal:  CNS Oncol       Date:  2019-01-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.